Or call
(888) 352-RUSH for help arranging an appointment.
Specialty:
Medical Oncology
Internal Medicine
Board Certification:
Medical Oncology
Internal Medicine
Faculty Rank: Professor
Medical or Graduate Education:
University of Illinois College of Medicine at Chicago
Residency:
Geisinger Medical Center - Internal Medicine
Fellowship:
Rush University Medical Center - Medical Oncology
Clinical Expertise:
Research Interests:
Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.
Multicenter trial of EC145 in advanced, folate-receptor positive adenocarcinoma of the lung. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Prognostic Significance of Weight Gain During Definitive Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients. Biomarkers of the Insulin-Like Growth Factor Pathway Predict Progression and Outcome in Lung Cancer. Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Lung cancer: new developments point the way to reduced mortality Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers Weight Gain in Advanced Non-Small-Cell Lung Cancer Patients During Treatment With Split-Course Concurrent Chemoradiotherapy is Associated With Superior Survival A multi-analyte serum test for the detection of non-small cell lung cancer Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer Implications of key trials in advanced nonsmall cell lung cancer Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer Epidermal growth factor receptor pathway PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients Pneumonectomy after chemoradiation therapy for non-small cell lung cancer: does "side" really matter? Apoptosis Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer Treatment of locally advanced non-small cell lung cancer Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib
To watch a brief video of Philip D. Bonomi, MD, click the play button at the lower left corner of the video frame below. (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
View Transcript We have a team of lung cancer specialists — radiation doctors, surgeons, medical oncologists, biochemists, pathologists, radiologists — and we work together.
I’m a strong believer in a Japanese proverb — there’s also an American proverb for this. Japanese say, “None of us is as smart as all of us.” We say, “Two heads are better than one.” So bringing experts together — the surgeons may look at something a little differently than I do. The radiation therapists and I may look at something different than they do. And then together we come and say, “This is what we think is best for this patient.”
Delivering that message from a team of experts at one time is a powerful message. And patients have given us a lot of feedback that they really appreciate it.
;){kind=link}
;){kind=link}
;){kind=link}
;){kind=link}
;){kind=link}
;){kind=link}